A Retrospective Analysis of Mortality in Subjects Who Participated in 3 Studies of Galantamine in Mild Cognitive Impairment.

Trial Profile

A Retrospective Analysis of Mortality in Subjects Who Participated in 3 Studies of Galantamine in Mild Cognitive Impairment.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2012

At a glance

  • Drugs Galantamine (Primary)
  • Indications Mild cognitive impairment
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 11 Apr 2012 Actual patient number changed from 2058 to 1083 as reported by ClinicalTrials.gov.
    • 11 Apr 2012 Additional trial locations identified as reported by ClinicalTrials.gov.
    • 15 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top